Corvus Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard A. Miller
- Full Time Employees
- 31
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 863 Mitten Road South San Francisco CA United States of America 94010
- IPO Date
- Mar 23, 2016
- CIK
- 0001626971
- Website
- corvuspharma.com
- Similar Companies
- Business
- Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company focused on developing novel ITK inhibition therapies and immuno-oncology agents to treat cancer and immune diseases. The company offers soquelitinib (CPI-818), a first-in-class oral selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) for relapsed/refractory peripheral T-cell lymphoma (PTCL), moderate-to-severe atopic dermatitis, autoimmune lymphoproliferative syndrome (ALPS), and planned applications in metastatic renal cell cancer (RCC); ciforadenant (CPI-444), an oral small-molecule antagonist of the adenosine A2A receptor for advanced RCC in combination with ipilimumab and nivolumab; and mupadolimab (CPI-006), a humanized monoclonal anti-CD73 antibody evaluated in non-small cell lung cancer that promotes adenosine blockade and B-cell activation. Incorporated in 2014 and headquartered in Burlingame, California, Corvus conducts operations primarily in the United States with a strategic collaboration partner, Angel Pharmaceuticals Co. Ltd. in China, for soquelitinib in T-cell lymphomas and mupadolimab commercialization. In recent developments, Corvus completed enrollment in extension Cohort 4 of its Phase 1/1b trial of soquelitinib in refractory T-cell lymphomas, with full dataset results, including 8-week data from 24 atopic dermatitis patients, expected in January 2026 ahead of an ASH conference presentation on T-cell lymphoma data; the company plans to initiate a Phase 2 trial in atopic dermatitis and a Phase 1b/2 trial in RCC in early 2026. Interim Phase 1 data from soquelitinib in atopic dermatitis demonstrated a favorable safety and efficacy profile in moderate-to-severe patients. Financially, Corvus narrowed its Q3 2025 net loss to $10.2 million from $40.2 million year-over-year, driven by R&D investments, while maintaining focus on partnerships and pipeline expansion amid ongoing Phase 3 PTCL evaluation.
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Moderate Buy” by Analysts
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% Following Weak Earnings
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains